Now showing items 1-1 of 1

    • Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. 

      Rosell, R; Dafni, U; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massutí, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; Coate, L; Barlesi, F; Rauch, D; Thomas, M; Camps, C; Gómez-Codina, J; Majem, M; Porta, R; Shah, R; Hanrahan, E; Kammler, R; Ruepp, B; Rabaglio, M; Kassapian, M; Karachaliou, N; Tam, R; Shames, DS; Molina-Vila, MA; Stahel, RA; BELIEF collaborative group (2017-05)
      BACKGROUND:The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the ...